In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avexxin AS

www.avexxin.com

Latest From Avexxin AS

Avexxin AS

Avexxin AS is betting that the novel molecular target identified by one of its co-founders will enable development of a drug capable of treating inflammatory skin diseases like psoriasis and perhaps, ultimately, more severe conditions such as rheumatoid arthritis. Its small molecule candidate is designed to block the intracellular enzyme group GIVαPLA2 to shut down the cytokine-mediated cascade that leads to production of the pro-inflammatory transcription factor nuclear factor-κB and eventually to the production of a better-known bad actor: tumor necrosis factor alpha.

BioPharmaceutical

New Orals, Better Topicals Top Psoriasis Wish List

Biologics for psoriasis leapfrogged existing treatments in the last decade, greatly improving the standard of care. Although those may still see incremental improvements, the real changes for patient care may come with the introduction of new oral and topical treatments. START-UP profiles four emerging companies that are tackling this challenge: Avexxin, Cellceutix, Creabilis, and Convoy Therapeutics.

BioPharmaceutical North America

Start-Up Previews, October 2012

This Month's Profile Group: New Orals, Better Topicals Top Psoriasis Wish List, features profiles of Avexxin, Cellceutix, Convoy Therapeutics, and Creabilis. Plus these Start-Ups Across Health Care: Domain Surgical, Ornim, Protagonist Therapeutics, SpineGuard, and Xcovery.

BioPharmaceutical Medical Device

Recent Financings Of Private Companies (03/2012)

START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical device sectors.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Avexxin AS
  • Senior Management
  • Mikael Orum, Pres. & CEO
    Berit Johansen, PhD, CSO
  • Contact Info
  • Avexxin AS
    Phone: 73 596 107
    Hogskoleringen 5
    Trondheim, N-7491
    Norway
Advertisement
Advertisement
UsernamePublicRestriction

Register